Acadian Asset Management’s Quince Therapeutics QNCX Stock Holding History

Acadian Asset Management’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$176K	Buy	8,754 +8,667	+9,962%	+$1.74M	﹤0.01%	1624
2025 Q4	$57K	Buy	+87	New	+$43.8K	﹤0.01%	1773
2023 Q2	–	Sell	-234	Closed	-$73K	–	1875
2023 Q1	$73K	Sell	234 -535	-70%	-$105K	﹤0.01%	1454
2022 Q4	$96K	Hold	769	–	–	﹤0.01%	1445
2022 Q3	$203K	Sell	769 -83	-10%	-$31.6K	﹤0.01%	1208
2022 Q2	$378K	Buy	+852	New	+$602K	﹤0.01%	1057

Other funds holding QNCX

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Acadian Asset Management's QNCX Position: Q1 2026 in Review

Acadian Asset Management increased its Quince Therapeutics (QNCX) stake by 9,962% in Q1 2026, buying an estimated $1.74M and bringing the position to 8,754 shares worth $176K. The position accounts for ﹤0.01% of the portfolio, ranked #1624.

Acadian Asset Management first reported a position in QNCX in Q2 2022 and has held it in 6 quarters since. The position peaked at $378K in Q2 2022. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

Acadian Asset Management held 8,754 shares of Quince Therapeutics worth $176K as of Q1 2026.
Acadian Asset Management bought 8,667 Quince Therapeutics shares in Q1 2026, an estimated $1.74M.
Quince Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #1624 holding.
Acadian Asset Management first reported a position in Quince Therapeutics in Q2 2022 and has held it in 6 quarters since.
Acadian Asset Management's Quince Therapeutics position peaked at $378K in Q2 2022.
43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.